What is Eloralintide?
An investigational selective amylin-receptor agonist studied in once-weekly phase 2 obesity trials.
Eloralintide in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?
24 registered trials · 3 indexed papers · 7 human / 2 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
Research context (as described)
- Amylin signaling is described as having roles in satiation, gastric emptying, glucose regulation and energy balance. Reviews of amylin analogs and calcitonin-family receptor biology provide broader context but do not replace compound-specific trial evidence.
Registered human trials (24)
Peer-reviewed studies (3)
| Paper | Authors | Journal | Year | Type |
|---|---|---|---|---|
| Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept | Bhattachar S et al. | Diabetes, obesity & metabolism | 2026 | Randomized Controlled Trial |
| Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial | Billings LK et al. | Lancet (London, England) | 2025 | Randomized Controlled Trial |
| Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept | Briere DA et al. | Molecular metabolism | 2025 | Randomized Controlled Trial |
More cited research
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (None, human RCT)
- A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance (2026, animal)
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in (2022, animal)
Conditions researched
- Fat loss, obesity & body recomposition
- Insulin resistance, prediabetes & type 2 diabetes
- Kidney protection (CKD, diabetic kidney, lupus kidney)
- Osteoarthritis, cartilage loss & avoiding joint replacement
- Sleep apnea (obstructive)
- Sleep problems (incl. insomnia on peptides)
Related compounds
- Retatrutide
- Tirzepatide
- Liraglutide
- Semaglutide
- ACTH (Corticotropin)
- ANP (Atrial Natriuretic Peptide)
- Ghrelin
- L-Carnitine
- Mazdutide
- Parathyroid Hormone (PTH 1-84)
FAQ
What is Eloralintide?
An investigational selective amylin-receptor agonist studied in once-weekly phase 2 obesity trials.
How many registered human trials study Eloralintide?
The PeptideWhiz trial index lists 24 registered trials for Eloralintide, the most recent from 2026.
How much published research exists on Eloralintide?
The PeptideWhiz paper index links 3 PubMed papers to Eloralintide; by study type, 7 human and 2 animal studies.
Which conditions is Eloralintide researched for?
Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Osteoarthritis, cartilage loss & avoiding joint replacement, Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides).
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).